文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 临床医学 > Zagouri 2015 Fulvestrant and male breast cancer
侵权投诉

Zagouri 2015 Fulvestrant and male breast cancer

270offulvestrantinmalebreastcancer,whereasonlylim-iteddataexistintheliteraturecomingfromcasereports/smallcaseserieswiththeuseofthisagentinmenwithbreastcancer.However,availableinvitrodataalongwiththemechanismofaction[5]indicatethatfulvestrantmayrepresentausefultreatmentoptionformalebreastcancerpatients.

Thisisthe rstpooledanalysisoftheliteraturetosyn-thesizeallavailabledataemergingfromcasereports/caseseriesandtoevaluatetheef cacyandsafetyoffulvestrantinmalebreastcancer.

Materialsandmethods

Selectionofstudiesanddataabstraction

ThispooledanalysiswasundertakenfollowingthePRISMAguidelines[8].Theprotocolofthispooledana-lysishasbeensubmittedtotheInstitutionalReviewBoardofAlexandraHospital,MedicalUniversityofAthens,Greeceandisavailableuponrequest.EligiblearticlesweresoughtinMEDLINE,uptoOctober15,2014.Thesearchstrategyincludedthefollowingalgorithm:breastAND(neoplasmsORneoplasmORcancerORcancersORcar-cinomaORcarcinomas))ANDfulvestrantAND(maleORmen).

Languagerestrictionswerenotapplied;twoinvestiga-tors(FZandDC),workingindependently,performedtheliteraturesearchandabstracteddatafromeligiblestudies.Reviewswerenoteligible,whileallprospectiveandret-rospectivestudies,aswellascasereports,wereconsideredeligible.Moreover,ina‘‘snowball’’procedure,weexam-inedallreferencesineligiblearticlesandinrelevantreviewsretrievedbyoursearch,identifyingpotentiallyeligibleconferenceabstracts.Casesoffulvestrantco-administrationwithotherhormonalagentswereexcludedfromthisanalysis.

Allstudiesexaminingtheef cacy(responseand/orsurvival)andsafety(adverseevents)offulvestrantinmalebreastcancerwereconsideredeligible,regardlessofsam-plesize.Evidently,studieswithfulvestrantadministrationinmalebreastcancerpatientswithoutreportinganydataregardingef cacyoradverseeventswereexcludedfromthisanalysis.Foreligiblestudies,thefollowingdatawerecollected: rstauthor,yearofpublication,doseoffulve-strantadministration,characteristicsofpatientpopulation(pathologicaltype,initialstage,grade,ER,PRandHER2status,ki-67),age(years),previoustreatments(hormonaltreatment,chemotherapy),lineoftreatment,response[completeresponse(CR),partialresponse(PR),stabiliza-tionofthedisease(SD),progressionofthedisease(PD)],typeofmetastases(visceral,bone)medianoverallsurvival

123

BreastCancerResTreat(2015)149:269–275

(OS)inmonths,medianprogression-freesurvival(PFS)inmonths,complications.Responseofdiseasewasde nedasstatedintheeligiblecasereports..

Regardingourpreviouspublicationonthetopic[9],additionaldatapertainingtotypeofmetastases(visceral,bone)andsideeffectswereprovidedforthispooledanalysis.

Quantitativesynthesisandstatistics

Regardingthequantitativesynthesis(pooledanalysis)ofthepublishedstudies,twosetsofcalculationswereper-formed.First,thedescriptivestatisticswerecalculated.Kaplan–MeiersurvivalcurveswereestimatedforPFS,forthegraphicalpresentationofresults.Second,factorspotentiallyassociatedwith(1)PFSand(2)clinicalbene t(PRandSDgroupedtogether,versusPD)wereevaluated;tothisend,univariateCoxregressionanalysesanduni-variatelogisticregressionanalyseswereperformed,respectively.Thepotentiallyprognosticfactorsthatwereevaluatedwerethefollowing:ageatfulvestrantadminis-tration,linesoftreatment,grade,initialstageatdiagnosis,HER2status,PRstatus,prioradjuvanthormonaltreatment,prioradjuvantchemotherapy,visceralmetastases,bonemetastases,hot ashes.Incaseofnotestimableoddsratios,duetothepresenceofazerocellinthecorresponding292table,thep-valueswerederivedfromFisher’sexacttest.

Thestatisticalanalysisshouldbedeemedexplorativegiventhesmallsamplesize,aswellasinlightofthequestionablecomparabilityofcasesamongthevariousstudies.StatisticalanalysiswasperformedwithSTATA/SE13statisticalsoftware(StataCorp,CollegeStation,TX,USA).

Results

Thesearchstrategyretrieved31articles.Ofthesearticles,19wereirrelevant,fourwerereviews,threewereexclu-dedduetovariousreasons[10–12](co-administrationoffulvestrantwithanotherhormonalagent[10],lackofdatapertainingtoef cacyorsafety[11,12])and vewereeligible[9,13–16].Aftersearchingthereferencesofallreviewsandremainingarticles,noadditionalconferenceabstracts/articleswereincluded.Overall, vestudies(23patients)wereeligibleforthispooledanalysis(Table1).TheaforementionedstepsareillustratedindetailinFig.1.

Themeanageofthestudysamplewas63.1years(SD:9.0,median64).Themajorityofpatients(86.7%)pre-sentedwithIDC,whereas13.3%presentedwithILC.Stageatinitialdiagnosiswasasfollows:stageI12.5%,II

上一页第2页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email